Fig. 5: Three Perturbations (P1-3) to reinforce the already activated ERK pathway activity in related cancers as a therapeutic approach.
From: ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
a Three suggested approaches to target the vulnerabilities to reinforced RTK/RAS/RAF pathway activation in affected cancers. b Framework for P3 target discovery is displayed in a more detailed manner. Figure generated in Biorender.
